Collegium Pharmaceutical and Bristol-Myers Squibb are both companies operating within the branded pharmaceuticals segment.
4 reports, 1 independent
Updated Aug 8
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Collegium Pharmaceutical and Bristol-Myers Squibb are both companies operating within the branded pharmaceuticals segment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Collegium Pharmaceutical (United States)
company in Dedham, United States
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.
Coverage
Newest first; wire copies grouped- StockStoryCollegium Pharmaceutical (COLL) Q2 Earnings: What To Expect Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings this Thursday morning. Here’s what you need to kno